NO20030153L - Blandinger som inneholder terapeutisk aktive komponenter som har foröket löselighet - Google Patents

Blandinger som inneholder terapeutisk aktive komponenter som har foröket löselighet

Info

Publication number: NO20030153L
Authority: NO; Norway
Prior art keywords: active components; therapeutically active; mixtures containing; increased solubility; containing therapeutically
Prior art date: 2000-07-14

Application number

NO20030153A

Other languages

English (en)

Other versions

NO331816B1 (no

NO20030153D0 (no

Inventor

Orest Olejnik

Edward D S Kerslake

Original Assignee

Allergan Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-07-14

Filing date

2003-01-13

Publication date

2003-01-13

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22814167&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20030153(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-01-13 Application filed by Allergan Inc filed Critical Allergan Inc

2003-01-13 Publication of NO20030153D0 publication Critical patent/NO20030153D0/no

2003-01-13 Publication of NO20030153L publication Critical patent/NO20030153L/no

2012-04-10 Publication of NO331816B1 publication Critical patent/NO331816B1/no

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Ophthalmology & Optometry (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Plural Heterocyclic Compounds (AREA)

NO20030153A 2000-07-14 2003-01-13 Blandinger som inneholder terapeutisk aktive komponenter som har foroket loselighet NO331816B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US21820600P	2000-07-14	2000-07-14
PCT/US2001/021551 WO2002005822A2 (en)	2000-07-14	2001-07-09	Compositions containing therapeutically active components having enhanced solubility

Publications (3)

Publication Number	Publication Date
NO20030153D0 NO20030153D0 (no)	2003-01-13
NO20030153L true NO20030153L (no)	2003-01-13
NO331816B1 NO331816B1 (no)	2012-04-10

Family

ID=22814167

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20030153A NO331816B1 (no)	2000-07-14	2003-01-13	Blandinger som inneholder terapeutisk aktive komponenter som har foroket loselighet

Country Status (23)

Country	Link
US (2)	US6562873B2 (no)
EP (2)	EP1301210A2 (no)
JP (1)	JP2004503593A (no)
KR (1)	KR20030023700A (no)
CN (1)	CN1441679A (no)
AR (1)	AR035039A1 (no)
AU (2)	AU7326801A (no)
BR (1)	BR0112461A (no)
CA (1)	CA2416169C (no)
CY (1)	CY1113391T1 (no)
DK (1)	DK2153819T3 (no)
ES (1)	ES2392636T3 (no)
HU (1)	HU230383B1 (no)
IL (2)	IL153322A0 (no)
MX (1)	MXPA02012206A (no)
NO (1)	NO331816B1 (no)
NZ (1)	NZ522610A (no)
PL (1)	PL361027A1 (no)
PT (1)	PT2153819E (no)
RU (1)	RU2291685C2 (no)
TW (1)	TWI287992B (no)
WO (1)	WO2002005822A2 (no)
ZA (1)	ZA200209877B (no)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR20030023700A (ko) *	2000-07-14	2003-03-19	알러간, 인코포레이티드	치료활성 성분을 함유하고 용해도가 증강된 조성물
US8858961B2 (en)	2000-07-14	2014-10-14	Allergan, Inc.	Compositions containing alpha-2-adrenergic agonist components
US20050026924A1 (en) *	2000-07-14	2005-02-03	Allergan, Inc.	Compositions containing alpha-2-adrenergic agonist components
NZ521185A (en) *	2000-07-14	2005-02-25	Allergan Inc	Compositions containing alpha-2-adrenergic agonist components
US20040214829A1 (en) *	2000-07-14	2004-10-28	Allergan, Inc.	Compositions containing alpha-2-adrenergic agonist components
US20050282774A1 (en) *	2000-10-31	2005-12-22	Eek Bjorn C	Method and pharmaceutical to treat spinal discs
US20030114460A1 (en) *	2001-12-14	2003-06-19	Allergan Sales, Inc.	Pharmaceutical conjugates with enhanced pharmacokinetic characteristics
US7642258B2 (en) *	2002-04-19	2010-01-05	Allergan, Inc.	Combination of brimonidine and timolol for topical ophthalmic use
US7030149B2 (en) *	2002-04-19	2006-04-18	Allergan, Inc.	Combination of brimonidine timolol for topical ophthalmic use
US6982079B2 (en)	2002-04-26	2006-01-03	Allergan, Inc.	Compositions for treating hyperemia
DK1534313T3 (da) *	2002-07-30	2013-02-04	Omeros Corp	Oftalmologiske irrigationsopløsninger og fremgangsmåde
US20040137079A1 (en) *	2003-01-08	2004-07-15	Cook James N.	Contact lens and eye drop rewetter compositions and methods
US20040191332A1 (en) *	2003-03-27	2004-09-30	Allergan, Inc.	Preserved ophthalmic compositions
US7811606B2 (en) *	2003-04-16	2010-10-12	Dey, L.P.	Nasal pharmaceutical formulations and methods of using the same
US9808471B2 (en) *	2003-04-16	2017-11-07	Mylan Specialty Lp	Nasal pharmaceutical formulations and methods of using the same
US8912174B2 (en) *	2003-04-16	2014-12-16	Mylan Pharmaceuticals Inc.	Formulations and methods for treating rhinosinusitis
US6933289B2 (en) *	2003-07-01	2005-08-23	Allergan, Inc.	Inhibition of irritating side effects associated with use of a topical ophthalmic medication
US20050059583A1 (en)	2003-09-15	2005-03-17	Allergan, Inc.	Methods of providing therapeutic effects using cyclosporin components
US7022740B2 (en) *	2004-04-29	2006-04-04	Leonard Mackles	Lubricious ophthalmic solutions
CA2505836C (en) *	2004-05-06	2013-08-27	Alcon Inc.	Topical brimonidine tartrate formulations that lack chlorine dioxide
US8569367B2 (en) *	2004-11-16	2013-10-29	Allergan, Inc.	Ophthalmic compositions and methods for treating eyes
US20080269353A1 (en) *	2005-07-13	2008-10-30	Santen Pharmaceutical Co., Ltd.	Preventative Composition For Ophthalmic Use
EP1956906A4 (en)	2005-11-09	2009-12-30	Combinatorx Inc	METHODS, COMPOSITIONS AND KITS FOR THE TREATMENT OF PATHOLOGIES
US20070238732A1 (en) *	2006-04-10	2007-10-11	Allergan, Inc.	Brimonidine and timolol compositions
US20080146497A1 (en) *	2006-07-25	2008-06-19	Graham Richard S	Cyclosporin Compositions
US9561178B2 (en) *	2006-07-25	2017-02-07	Allergan, Inc.	Cyclosporin compositions
US9125807B2 (en)	2007-07-09	2015-09-08	Incept Llc	Adhesive hydrogels for ophthalmic drug delivery
BRPI0912985A2 (pt) *	2008-05-19	2015-10-13	Alcon Res Ltd	composições farmacêuticas com polímero de carboxivinila e polímero de povidona
US20110244058A1 (en) *	2008-08-01	2011-10-06	Gerald Horn	Compositions and methods for treatment of pulmonary diseases and conditions
US20100203165A1 (en)	2008-08-01	2010-08-12	Gerald Horn	Compositions and methods for treatment of disorders or conditions of the eye
WO2010014552A1 (en)	2008-08-01	2010-02-04	Alpha Synergy Development, Inc.	Vasoconstriction compositions and methods of use
US12246013B2 (en)	2008-08-01	2025-03-11	Eye Therapies Llc	Vasoconstriction compositions and methods of use
US20100197694A1 (en) *	2008-08-01	2010-08-05	Gerald Horn	Compositions and methods for treatment of diseases and conditions with increased vascular permeability
US20100202979A1 (en) *	2008-08-01	2010-08-12	Gerald Horn	Compositions and methods for treatment of pulmonary diseases and conditions
US20110003823A1 (en) *	2008-08-01	2011-01-06	Alpha Synergy Development, Inc.	Compositions and methods for treatment of diseases and conditions associated with vasodilation and/or vascular leakage
US8952011B2 (en)	2008-08-01	2015-02-10	Eye Therapies Llc	Compositions and methods for the treatment of nasal conditions
EP2396070B1 (en)	2009-02-12	2024-12-04	Incept Llc	Drug delivery through hydrogel plugs
US8987270B2 (en)	2009-07-27	2015-03-24	Eye Therapies Llc	Formulations of selective alpha-2 agonists and methods of use thereof
WO2011075621A1 (en) *	2009-12-17	2011-06-23	Alpha Synergy Development, Inc.	Compositions and methods for ophthalmic delivery of nasal decongestants
US9522153B2 (en)	2009-12-22	2016-12-20	Allergan, Inc.	Compositions and methods for lowering intraocular pressure
US9931296B2 (en)	2010-04-03	2018-04-03	Praful Doshi	Medical devices including medicaments and methods of making and using same
US10413506B2 (en)	2010-04-03	2019-09-17	Praful Doshi	Medical devices including medicaments and methods of making and using same including enhancing comfort, enhancing drug penetration, and treatment of myopia
KR20130092957A (ko) *	2010-04-07	2013-08-21	알러간, 인코포레이티드	안과용 처방용 보존제 조성물의 조합
US8961501B2 (en)	2010-09-17	2015-02-24	Incept, Llc	Method for applying flowable hydrogels to a cornea
WO2012041910A1 (de)	2010-10-01	2012-04-05	Elektra Management S.R.O.	Lösung von guanidinium-verbindungen, verfahren unter einsatz dieser lösung sowie deren verwendung
US8445526B2 (en)	2011-02-03	2013-05-21	Glaucoma & Nasal Therapies Llc	Compositions and methods for treatment of glaucoma
US10226417B2 (en)	2011-09-16	2019-03-12	Peter Jarrett	Drug delivery systems and applications
US8957048B2 (en)	2011-10-06	2015-02-17	Allergan, Inc.	Compositions for the treatment of dry eye
US9907826B2 (en)	2011-12-07	2018-03-06	Allergan, Inc.	Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
SI2787968T1 (sl)	2011-12-07	2020-08-31	Allergan, Inc.	Učinkovita dostava lipida človeškemu solznemu filmu z uporabo sol-občutljivega emulzijskega sistema
JP5933033B2 (ja)	2012-01-20	2016-06-08	アラタナセラピューティクスエンヴェー	点眼剤組成物
AU2013201465B2 (en)	2012-10-24	2016-03-03	Rayner Intraocular Lenses Limited	Stable preservative-free mydriatic and anti-inflammatory solutions for injection
US8999938B2 (en)	2013-06-21	2015-04-07	Gnt Llc	Ophthalmic lipophilic drug delivery vehicle formulations
EP3086776B1 (en)	2013-12-24	2020-06-17	Sentiss Pharma Private Limited	Topical brimonidine tartrate ophthalmic solution
KR102487299B1 (ko)	2014-11-25	2023-01-10	알러간, 인코포레이티드	안정화된 오메가-3 안과용 조성물
TWI705812B (zh)	2014-12-01	2020-10-01	奥默羅斯公司	用於抑制術後眼睛炎性病況的抗炎和散瞳前房溶液
US20180078500A1 (en) *	2015-03-19	2018-03-22	Allergan, Inc.	Fixed dose combination of brimonidine and timolol
CN109862851A (zh)	2016-08-12	2019-06-07	蚕丝科技有限公司	用于治疗炎症的丝衍生蛋白质
PL3548000T3 (pl) *	2017-05-11	2022-01-17	Vyluma Inc.	Kompozycja farmaceutyczna atropiny
GR1009419B (el)	2017-11-07	2018-12-14	Φαρματεν Αβεε	Οφθαλμικο φαρμακευτικο σκευασμα που περιεχει εναν συνδυασμο βρινζολαμιδης και βριμονιδινης και μεθοδος για την παρασκευη αυτου
UA129938C2 (uk)	2020-04-29	2025-09-17	Сентісс Фарма Прайвет Лімітед	Офтальмологічні композиції, що містять комбінацію бринзоламіду та бримонідину
GR1010024B (el) *	2020-05-06	2021-06-01	Φαρματεν Α.Β.Ε.Ε.	Φαρμακευτικο σκευασμα ελευθερο συντηρητικου για οφθαλμικη χορηγηση που περιλαμβανει βριμονιδινη
WO2021235527A1 (ja) *	2020-05-20	2021-11-25	アイ・セラピーズ・エル・エル・シー	ブリモニジンを含有する液体製剤
JP2022123792A (ja) *	2021-02-12	2022-08-24	参天製薬株式会社	水性医薬組成物

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE1154119B (de) *	1961-11-30	1963-09-12	Boehringer Sohn Ingelheim	Verfahren zur Herstellung von 2-(2', 4', 6'-Trimethylbenzyl)-1, 3-diazacyclopenten-(2) und seinen Salzen
US3278447A (en)	1963-12-02	1966-10-11	Cloro Bac Products Inc	Process for stabilizing chlorine dioxide solution
BE795970A (fr)	1972-02-29	1973-08-27	Pfizer	Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant
US4089969A (en)	1976-07-14	1978-05-16	Syntex (U.S.A.) Inc.	5-Aroyl-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylic acid derivatives and process for the production thereof
JPS542338A (en) *	1977-04-22	1979-01-09	Sandoz Ag	Pharmaceutical composition
US4474787A (en)	1977-05-04	1984-10-02	Fisons Limited	7,6 Dioxo-4H,6H-pyrano[3,2-g]quinoline dicarboxylic acids and anti-allergic use thereof
JPS5746986A (en)	1980-09-02	1982-03-17	Dai Ichi Seiyaku Co Ltd	Pyrido(1,2,3-de)(1,4)benzoxazine derivative
US4530920A (en)	1983-11-07	1985-07-23	Syntex (U.S.A.) Inc.	Nonapeptide and decapeptide analogs of LHRH, useful as LHRH agonist
US4806556A (en)	1985-12-12	1989-02-21	Regents Of The University Of Minnesota	Gut-selective opiates
US5089509A (en)	1988-09-15	1992-02-18	Allergan, Inc.	Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity
DE3731255A1 (de) *	1987-09-17	1989-04-06	Boehringer Ingelheim Int	Stabilisierung von therapeutisch wirksamen proteinen in pharmazeutischen zubereitungen
US5719197A (en) *	1988-03-04	1998-02-17	Noven Pharmaceuticals, Inc.	Compositions and methods for topical administration of pharmaceutically active agents
US5607698A (en)	1988-08-04	1997-03-04	Ciba-Geigy Corporation	Method of preserving ophthalmic solution and compositions therefor
CA2007181C (en)	1989-01-06	1998-11-24	Angelo Mario Morella	Sustained release pharmaceutical composition
US5202128A (en)	1989-01-06	1993-04-13	F. H. Faulding & Co. Limited	Sustained release pharmaceutical composition
US5352796A (en)	1989-10-30	1994-10-04	The Salk Institute For Biological Studies	Amino acids useful in making GnRH analogs
US5021416A (en)	1989-10-31	1991-06-04	Allergan, Inc.	Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure
GB9017353D0 (en)	1990-08-08	1990-09-19	Merck Sharp & Dohme	Chemical process
RU2079304C1 (ru) *	1990-11-08	1997-05-20	Фудзисава Фармасьютикал Ко., Лтд.	Фармацевтическая композиция, обладающая иммуносупрессорной и антимикробной активностями
JPH07508716A (ja)	1992-04-21	1995-09-28	ザ　スキーペンズ　アイ　リサーチ　インスティテュート，インコーポレイテッド	シェーグレン症候群における眼のアンドロゲン療法
US5459133A (en)	1992-06-05	1995-10-17	Telor Ophthalmic Pharmaceuticals, Inc.	Methods and products for treating presbyopia
US5688819A (en)	1992-09-21	1997-11-18	Allergan	Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5922773A (en)	1992-12-04	1999-07-13	The Children's Medical Center Corp.	Glaucoma treatment
AU6124494A (en)	1993-01-28	1994-08-15	University Of Iowa Research Foundation, The	Ophthalmic uses of signa agonists
AU688380B2 (en)	1993-10-13	1998-03-12	Allergan, Inc.	Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
US5994110A (en)	1995-02-10	1999-11-30	Mosbach; Klaus	Methods for direct synthesis of compounds having complementary structure to a desired molecular entity and use thereof
US5474979A (en)	1994-05-17	1995-12-12	Allergan, Inc.	Nonirritating emulsions for sensitive tissue
ZA965837B (en)	1995-07-11	1997-01-31	Merck & Co Inc	A triazolylmethyl-indole ethylamine bisulfate salt
US5952345A (en)	1995-09-01	1999-09-14	Allergan Sales, Inc.	Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
US5675024A (en)	1995-11-22	1997-10-07	Allergan	Aryl or heteroaryl amides of tetrahydronaphthalene, chroman, thiochroman and 1,2,3,4,-tetrahydroquinoline carboxylic acids, having an electron withdrawing substituent in the aromatic or heteroaromatic moiety, having retinoid-like biological activity
EP0834308A1 (en)	1996-09-30	1998-04-08	LG Chemical Limited	Ophthalmic formulation for treating myopia comprising dopamine agonist and cyclodextrin
JP2001522358A (ja)	1997-04-18	2001-11-13	アボツト・ラボラトリーズ	高純度６，７−ジクロロ−５−ニトロ−２，３−ジヒドロキノキサリン−２，３−ジオンの調製方法
AU2870899A (en)	1998-02-26	1999-09-15	Abbott Laboratories	Oral formulation for hydrophilic drugs
DK1069913T3 (da)	1998-04-07	2003-11-17	Alcon Mfg Ltd	Gelatinering af ophthalmiske sammensætninger indeholdende xanthangummi
WO2000012137A1 (en) *	1998-09-02	2000-03-09	Allergan Sales, Inc.	Preserved cyclodextrin-containing compositions
DE69923987T2 (de) *	1998-10-08	2006-11-02	Karagoezian, Hampar L., San Juan Capistrano	Synergistische antimikrobielle, dermatologische und ophtahalmologische zubereitung, die ein chlorit und wasserstoffperoxid enthalten
US6514504B1 (en) *	1999-08-18	2003-02-04	The Procter & Gamble Company	Discontinuous films from skin care compositions
KR20030023700A (ko) *	2000-07-14	2003-03-19	알러간, 인코포레이티드	치료활성 성분을 함유하고 용해도가 증강된 조성물
NZ521185A (en) *	2000-07-14	2005-02-25	Allergan Inc	Compositions containing alpha-2-adrenergic agonist components

2001
- 2001-07-09 KR KR10-2003-7000535A patent/KR20030023700A/ko not_active Ceased
- 2001-07-09 PL PL36102701A patent/PL361027A1/xx not_active Application Discontinuation
- 2001-07-09 DK DK09176049.6T patent/DK2153819T3/da active
- 2001-07-09 RU RU2003101320/15A patent/RU2291685C2/ru active
- 2001-07-09 PT PT09176049T patent/PT2153819E/pt unknown
- 2001-07-09 WO PCT/US2001/021551 patent/WO2002005822A2/en not_active Ceased
- 2001-07-09 NZ NZ522610A patent/NZ522610A/en not_active IP Right Cessation
- 2001-07-09 JP JP2002511754A patent/JP2004503593A/ja not_active Withdrawn
- 2001-07-09 EP EP01952527A patent/EP1301210A2/en not_active Ceased
- 2001-07-09 CA CA002416169A patent/CA2416169C/en not_active Expired - Lifetime
- 2001-07-09 IL IL15332201A patent/IL153322A0/xx active IP Right Grant
- 2001-07-09 HU HU0301405A patent/HU230383B1/hu unknown
- 2001-07-09 AU AU7326801A patent/AU7326801A/xx active Pending
- 2001-07-09 CN CN01812829A patent/CN1441679A/zh active Pending
- 2001-07-09 MX MXPA02012206A patent/MXPA02012206A/es active IP Right Grant
- 2001-07-09 BR BR0112461-7A patent/BR0112461A/pt not_active Application Discontinuation
- 2001-07-09 AU AU2001273268A patent/AU2001273268B2/en not_active Expired
- 2001-07-09 ES ES09176049T patent/ES2392636T3/es not_active Expired - Lifetime
- 2001-07-09 EP EP09176049A patent/EP2153819B1/en not_active Expired - Lifetime
- 2001-07-10 US US09/903,962 patent/US6562873B2/en not_active Expired - Lifetime
- 2001-07-13 TW TW090117219A patent/TWI287992B/zh not_active IP Right Cessation
- 2001-07-13 AR ARP010103345A patent/AR035039A1/es not_active Application Discontinuation
2002
- 2002-12-05 ZA ZA200209877A patent/ZA200209877B/en unknown
- 2002-12-08 IL IL153322A patent/IL153322A/en unknown
2003
- 2003-01-13 NO NO20030153A patent/NO331816B1/no not_active IP Right Cessation
- 2003-02-24 US US10/373,275 patent/US20030153530A1/en not_active Abandoned
2012
- 2012-11-21 CY CY20121101120T patent/CY1113391T1/el unknown

Also Published As

Publication number	Publication date
CY1113391T1 (el)	2016-06-22
EP1301210A2 (en)	2003-04-16
HU230383B1 (hu)	2016-03-29
DK2153819T3 (da)	2012-12-03
CN1441679A (zh)	2003-09-10
KR20030023700A (ko)	2003-03-19
AR035039A1 (es)	2004-04-14
CA2416169C (en)	2008-09-23
IL153322A (en)	2011-01-31
NZ522610A (en)	2004-11-26
EP2153819A3 (en)	2010-05-12
CA2416169A1 (en)	2002-01-24
HUP0301405A2 (hu)	2003-08-28
PT2153819E (pt)	2012-11-14
HUP0301405A3 (en)	2006-02-28
IL153322A0 (en)	2003-07-06
US6562873B2 (en)	2003-05-13
EP2153819A2 (en)	2010-02-17
NO331816B1 (no)	2012-04-10
US20030153530A1 (en)	2003-08-14
AU2001273268B2 (en)	2005-08-25
NO20030153D0 (no)	2003-01-13
TWI287992B (en)	2007-10-11
US20020071874A1 (en)	2002-06-13
MXPA02012206A (es)	2003-06-04
BR0112461A (pt)	2003-07-22
WO2002005822A2 (en)	2002-01-24
ES2392636T3 (es)	2012-12-12
PL361027A1 (en)	2004-09-20
RU2291685C2 (ru)	2007-01-20
AU7326801A (en)	2002-01-30
JP2004503593A (ja)	2004-02-05
EP2153819B1 (en)	2012-09-05
WO2002005822A3 (en)	2002-05-02
ZA200209877B (en)	2003-09-29

Publication	Publication Date	Title
NO20030153L (no)	2003-01-13	Blandinger som inneholder terapeutisk aktive komponenter som har foröket löselighet
NO20032101D0 (no)	2003-05-09	Apoliprotein analoger
ITMI20011489A0 (it)	2001-07-12	Miscele stabilizzanti
NO20026195D0 (no)	2002-12-23	Substituerte-triazolopyrimidiner som anticancer midler
DK1317177T3 (da)	2004-12-20	Desinficerende formuleringer
AR028291A1 (es)	2003-04-30	Formulaciones oftalmicas
NO20042807L (no)	2004-07-02	Farmasoytiske sammensetninger som innbefatter aktive vitamin D forbindelser
NO20026037L (no)	2003-02-06	Sötvareprodukt som inneholder aktive bestanddeler
NO20014759L (no)	2001-11-29	C(7)-estersubstituerte taxaner som antitumormidler
NO20033969L (no)	2003-10-13	Triazolpyridiner som anti-inflammatoriske midler
DE60110855D1 (de)	2005-06-23	Wellenlängenstabilisierte Laseranordnung
NO20032613D0 (no)	2003-06-10	Farmasöytisk sammensetning som har en forbedret vannopplöselighet
DE60135103D1 (de)	2008-09-11	Endoskopische stabilisierungsvorrichtung
MXPA03001425A (es)	2003-06-06	Compuestos farmaceuticos.
DE50213466D1 (de)	2009-05-28	Fungizide wirkstoffkombinationen
DK1429607T3 (da)	2007-08-13	Delta-1-pyrroliner som pesticider
NO20032614L (no)	2003-08-05	Farmasöytisk sammensetning som har forbedret absorberbarhet
NL1018186A1 (nl)	2001-12-03	Stabilisatormengsels.
ATE270043T1 (de)	2004-07-15	Fungizide wirkstoffkombinationen
NL1018187A1 (nl)	2001-12-03	Stabilisatormengsels.
DK1330458T3 (da)	2009-09-21	N-(1,2,4-triazoloazinyl)thiophensulfonamidforbindelser som herbicider
NO20012965D0 (no)	2001-06-15	Sulfonyloksazolaminer som terapeutisk aktive forbindelser
NL1018188A1 (nl)	2001-12-03	Stabilisatormengsels.
NO20013441D0 (no)	2001-07-11	Sammensetninger som har forbedret stabilitet
PT1315420E (pt)	2006-08-31	Misturas herbicidas

Legal Events

Date	Code	Title	Description
2021-08-09	MK1K	Patent expired